Exploration of Nirmatrelvir Derivatives as Optimized SARS-CoV-2 Antivirals.

Alugubelli YR, Vulupala VR, Yang KS, Khatua K, Blankenship LR, Kumar S, Coleman D, Guo X, Geng ZZ, Cho CD, Sankaran B, Neuman BW, Xu S, Liu WR

Open source

DOI: 10.1002/cmdc.70424
Published: 2026 Aug 14
Container: ChemMedChem
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cmdc.70424,
  title = {Exploration of Nirmatrelvir Derivatives as Optimized SARS-CoV-2 Antivirals.},
  author = {Alugubelli YR and Vulupala VR and Yang KS and Khatua K and Blankenship LR and Kumar S and Coleman D and Guo X and Geng ZZ and Cho CD and Sankaran B and Neuman BW and Xu S and Liu WR},
  year = {2026},
  journal = {ChemMedChem},
  doi = {10.1002/cmdc.70424},
  url = {https://doi.org/10.1002/cmdc.70424}
}

RIS

TY  - JOUR
TI  - Exploration of Nirmatrelvir Derivatives as Optimized SARS-CoV-2 Antivirals.
AU  - Alugubelli YR
AU  - Vulupala VR
AU  - Yang KS
AU  - Khatua K
AU  - Blankenship LR
AU  - Kumar S
AU  - Coleman D
AU  - Guo X
AU  - Geng ZZ
AU  - Cho CD
AU  - Sankaran B
AU  - Neuman BW
AU  - Xu S
AU  - Liu WR
PY  - 2026
JO  - ChemMedChem
DO  - 10.1002/cmdc.70424
UR  - https://doi.org/10.1002/cmdc.70424
ER  -

APA

YR, A., VR, V., KS, Y., K, K., LR, B., S, K., D, C., X, G., ZZ, G., CD, C., B, S., BW, N., S, X., & WR, L. (2026). Exploration of Nirmatrelvir Derivatives as Optimized SARS-CoV-2 Antivirals.. ChemMedChem. https://doi.org/10.1002/cmdc.70424

Source records

pubmed · retrieved 2026-09-26T17:47:51.458Z